Cargando…
Pharmacokinetic Modeling of (R)-[(11)C]verapamil to Measure the P-Glycoprotein Function in Nonhuman Primates
[Image: see text] (R)-[(11)C]verapamil is a radiotracer widely used for the evaluation of the P-glycoprotein (P-gp) function at the blood–brain barrier (BBB). Several studies have evaluated the pharmacokinetics of (R)-[(11)C]verapamil in rats and humans under different conditions. However, to the be...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2020
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788571/ https://www.ncbi.nlm.nih.gov/pubmed/33315404 http://dx.doi.org/10.1021/acs.molpharmaceut.0c01014 |
_version_ | 1783633055540314112 |
---|---|
author | García-Varela, Lara García, David Vállez Kakiuchi, Takeharu Ohba, Hiroyuki Nishiyama, Shingo Tago, Tetsuro Elsinga, Philip H. Tsukada, Hideo Colabufo, Nicola A. Dierckx, Rudi A.J.O. van Waarde, Aren Toyohara, Jun Boellaard, Ronald Luurtsema, Gert |
author_facet | García-Varela, Lara García, David Vállez Kakiuchi, Takeharu Ohba, Hiroyuki Nishiyama, Shingo Tago, Tetsuro Elsinga, Philip H. Tsukada, Hideo Colabufo, Nicola A. Dierckx, Rudi A.J.O. van Waarde, Aren Toyohara, Jun Boellaard, Ronald Luurtsema, Gert |
author_sort | García-Varela, Lara |
collection | PubMed |
description | [Image: see text] (R)-[(11)C]verapamil is a radiotracer widely used for the evaluation of the P-glycoprotein (P-gp) function at the blood–brain barrier (BBB). Several studies have evaluated the pharmacokinetics of (R)-[(11)C]verapamil in rats and humans under different conditions. However, to the best of our knowledge, the pharmacokinetics of (R)-[(11)C]verapamil have not yet been evaluated in nonhuman primates. Our study aims to establish (R)-[(11)C]verapamil as a reference P-gp tracer for comparison of a newly developed P-gp positron emission tomography (PET) tracer in a species close to humans. Therefore, the study assesses the kinetics of (R)-[(11)C]verapamil and evaluates the effect of scan duration and P-gp inhibition on estimated pharmacokinetic parameters. Three nonhuman primates underwent two dynamic 91 min PET scans with arterial blood sampling, one at baseline and another after inhibition of the P-gp function. The (R)-[(11)C]verapamil data were analyzed using 1-tissue compartment model (1-TCM) and 2-tissue compartment model fits using plasma-corrected for polar radio-metabolites or non-corrected for radio-metabolites as an input function and with various scan durations (10, 20, 30, 60, and 91 min). The preferred model was chosen according to the Akaike information criterion and the standard errors (SE %) of the estimated parameters. 1-TCM was selected as the model of choice to analyze the (R)-[(11)C]verapamil data at baseline and after inhibition and for all scan durations tested. The volume of distribution (V(T)) and the efflux constant k(2) estimations were affected by the evaluated scan durations, whereas the influx constant K(1) estimations remained relatively constant. After P-gp inhibition (tariquidar, 8 mg/kg), in a 91 min scan duration, the whole-brain V(T) increased significantly up to 208% (p < 0.001) and K(1) up to 159% (p < 0.001) compared with baseline scans. The k(2) values decreased significantly after P-gp inhibition in all the scan durations except for the 91 min scans. This study suggests the use of K(1), calculated with 1-TCM and using short PET scans (10 to 30 min), as a suitable parameter to measure the P-gp function at the BBB of nonhuman primates. |
format | Online Article Text |
id | pubmed-7788571 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Chemical
Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-77885712021-01-07 Pharmacokinetic Modeling of (R)-[(11)C]verapamil to Measure the P-Glycoprotein Function in Nonhuman Primates García-Varela, Lara García, David Vállez Kakiuchi, Takeharu Ohba, Hiroyuki Nishiyama, Shingo Tago, Tetsuro Elsinga, Philip H. Tsukada, Hideo Colabufo, Nicola A. Dierckx, Rudi A.J.O. van Waarde, Aren Toyohara, Jun Boellaard, Ronald Luurtsema, Gert Mol Pharm [Image: see text] (R)-[(11)C]verapamil is a radiotracer widely used for the evaluation of the P-glycoprotein (P-gp) function at the blood–brain barrier (BBB). Several studies have evaluated the pharmacokinetics of (R)-[(11)C]verapamil in rats and humans under different conditions. However, to the best of our knowledge, the pharmacokinetics of (R)-[(11)C]verapamil have not yet been evaluated in nonhuman primates. Our study aims to establish (R)-[(11)C]verapamil as a reference P-gp tracer for comparison of a newly developed P-gp positron emission tomography (PET) tracer in a species close to humans. Therefore, the study assesses the kinetics of (R)-[(11)C]verapamil and evaluates the effect of scan duration and P-gp inhibition on estimated pharmacokinetic parameters. Three nonhuman primates underwent two dynamic 91 min PET scans with arterial blood sampling, one at baseline and another after inhibition of the P-gp function. The (R)-[(11)C]verapamil data were analyzed using 1-tissue compartment model (1-TCM) and 2-tissue compartment model fits using plasma-corrected for polar radio-metabolites or non-corrected for radio-metabolites as an input function and with various scan durations (10, 20, 30, 60, and 91 min). The preferred model was chosen according to the Akaike information criterion and the standard errors (SE %) of the estimated parameters. 1-TCM was selected as the model of choice to analyze the (R)-[(11)C]verapamil data at baseline and after inhibition and for all scan durations tested. The volume of distribution (V(T)) and the efflux constant k(2) estimations were affected by the evaluated scan durations, whereas the influx constant K(1) estimations remained relatively constant. After P-gp inhibition (tariquidar, 8 mg/kg), in a 91 min scan duration, the whole-brain V(T) increased significantly up to 208% (p < 0.001) and K(1) up to 159% (p < 0.001) compared with baseline scans. The k(2) values decreased significantly after P-gp inhibition in all the scan durations except for the 91 min scans. This study suggests the use of K(1), calculated with 1-TCM and using short PET scans (10 to 30 min), as a suitable parameter to measure the P-gp function at the BBB of nonhuman primates. American Chemical Society 2020-12-14 2021-01-04 /pmc/articles/PMC7788571/ /pubmed/33315404 http://dx.doi.org/10.1021/acs.molpharmaceut.0c01014 Text en © 2020 American Chemical Society This is an open access article published under a Creative Commons Non-Commercial No Derivative Works (CC-BY-NC-ND) Attribution License (http://pubs.acs.org/page/policy/authorchoice_ccbyncnd_termsofuse.html) , which permits copying and redistribution of the article, and creation of adaptations, all for non-commercial purposes. |
spellingShingle | García-Varela, Lara García, David Vállez Kakiuchi, Takeharu Ohba, Hiroyuki Nishiyama, Shingo Tago, Tetsuro Elsinga, Philip H. Tsukada, Hideo Colabufo, Nicola A. Dierckx, Rudi A.J.O. van Waarde, Aren Toyohara, Jun Boellaard, Ronald Luurtsema, Gert Pharmacokinetic Modeling of (R)-[(11)C]verapamil to Measure the P-Glycoprotein Function in Nonhuman Primates |
title | Pharmacokinetic Modeling of (R)-[(11)C]verapamil to Measure the P-Glycoprotein Function
in Nonhuman Primates |
title_full | Pharmacokinetic Modeling of (R)-[(11)C]verapamil to Measure the P-Glycoprotein Function
in Nonhuman Primates |
title_fullStr | Pharmacokinetic Modeling of (R)-[(11)C]verapamil to Measure the P-Glycoprotein Function
in Nonhuman Primates |
title_full_unstemmed | Pharmacokinetic Modeling of (R)-[(11)C]verapamil to Measure the P-Glycoprotein Function
in Nonhuman Primates |
title_short | Pharmacokinetic Modeling of (R)-[(11)C]verapamil to Measure the P-Glycoprotein Function
in Nonhuman Primates |
title_sort | pharmacokinetic modeling of (r)-[(11)c]verapamil to measure the p-glycoprotein function
in nonhuman primates |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788571/ https://www.ncbi.nlm.nih.gov/pubmed/33315404 http://dx.doi.org/10.1021/acs.molpharmaceut.0c01014 |
work_keys_str_mv | AT garciavarelalara pharmacokineticmodelingofr11cverapamiltomeasurethepglycoproteinfunctioninnonhumanprimates AT garciadavidvallez pharmacokineticmodelingofr11cverapamiltomeasurethepglycoproteinfunctioninnonhumanprimates AT kakiuchitakeharu pharmacokineticmodelingofr11cverapamiltomeasurethepglycoproteinfunctioninnonhumanprimates AT ohbahiroyuki pharmacokineticmodelingofr11cverapamiltomeasurethepglycoproteinfunctioninnonhumanprimates AT nishiyamashingo pharmacokineticmodelingofr11cverapamiltomeasurethepglycoproteinfunctioninnonhumanprimates AT tagotetsuro pharmacokineticmodelingofr11cverapamiltomeasurethepglycoproteinfunctioninnonhumanprimates AT elsingaphiliph pharmacokineticmodelingofr11cverapamiltomeasurethepglycoproteinfunctioninnonhumanprimates AT tsukadahideo pharmacokineticmodelingofr11cverapamiltomeasurethepglycoproteinfunctioninnonhumanprimates AT colabufonicolaa pharmacokineticmodelingofr11cverapamiltomeasurethepglycoproteinfunctioninnonhumanprimates AT dierckxrudiajo pharmacokineticmodelingofr11cverapamiltomeasurethepglycoproteinfunctioninnonhumanprimates AT vanwaardearen pharmacokineticmodelingofr11cverapamiltomeasurethepglycoproteinfunctioninnonhumanprimates AT toyoharajun pharmacokineticmodelingofr11cverapamiltomeasurethepglycoproteinfunctioninnonhumanprimates AT boellaardronald pharmacokineticmodelingofr11cverapamiltomeasurethepglycoproteinfunctioninnonhumanprimates AT luurtsemagert pharmacokineticmodelingofr11cverapamiltomeasurethepglycoproteinfunctioninnonhumanprimates |